JP6321962B2 - Cosmetic composition containing oleanolic acid - Google Patents
Cosmetic composition containing oleanolic acid Download PDFInfo
- Publication number
- JP6321962B2 JP6321962B2 JP2013539759A JP2013539759A JP6321962B2 JP 6321962 B2 JP6321962 B2 JP 6321962B2 JP 2013539759 A JP2013539759 A JP 2013539759A JP 2013539759 A JP2013539759 A JP 2013539759A JP 6321962 B2 JP6321962 B2 JP 6321962B2
- Authority
- JP
- Japan
- Prior art keywords
- oleanolic acid
- cosmetic composition
- nanoliposomes
- composition according
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 67
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims description 51
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title claims description 51
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title claims description 51
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title claims description 51
- 229940100243 oleanolic acid Drugs 0.000 title claims description 51
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title claims description 51
- 239000002537 cosmetic Substances 0.000 title claims description 47
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- 230000036570 collagen biosynthesis Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000002994 raw material Substances 0.000 description 6
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- -1 alkyl acyl glutamate Chemical compound 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 2
- 229940033329 phytosphingosine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IPVNPUHVCZJVOI-VJSFXXLFSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 IPVNPUHVCZJVOI-VJSFXXLFSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 229940080277 cholesteryl sulfate Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
Description
本発明は、シワ改善の有効成分としてナノリポソーム内に捕集したオレアノール酸を含有する可溶化化粧料組成物に関する。 The present invention relates to a solubilized cosmetic composition containing oleanolic acid collected in nanoliposomes as an active ingredient for improving wrinkles.
皮膚は、人体の一次防御膜であって、体内の諸器官を温度及び湿度変化や、紫外線、公害物質など外部環境の刺激から保護し、且つ、体温調節などの生体恒常性の維持にも重要な役割をしている。しかし、外部から受ける過度な物理的・化学的刺激及びストレス、栄養欠乏などは、皮膚の正常機能を低下させ、弾力損失、角質化、シワ生成などの皮膚老化現象を促進させることになる。このような現象を防止してより健康で且つ弾力のある皮膚を保つために、従来に使用された殆どの化粧料は、効能が微弱であったり皮膚の副作用を誘発するなど様々な問題点を有していた(韓国特許公開10−2010−0064451)。 The skin is the primary protective film of the human body, protecting various organs in the body from changes in temperature and humidity, ultraviolet rays, pollutants, and other external environmental stimuli, and also important for maintaining homeostasis such as body temperature regulation. Has a role to play. However, excessive physical and chemical stimuli, stress, and nutritional deficiencies received from the outside reduce the normal function of the skin and promote skin aging phenomena such as loss of elasticity, keratinization, and generation of wrinkles. In order to prevent such a phenomenon and maintain a healthier and more elastic skin, most of the cosmetics used in the past have various problems such as weak efficacy and inducing side effects on the skin. (Korean Patent Publication 10-2010-0064451).
皮膚の副作用を誘発しないながら、皮膚の老化防止効果を有する原料に対する研究が活発に進められている中、オレアノール酸を皮膚化粧料組成物に適用して優れた皮膚の老化防止効果を示すことを発見した。ヒドロキシ5環性テルペンの一種類であるオレアノール酸は、Eriobotrya japonica(loquata)、Perilla frutescens、Staphyleaholocarpaなどの多くの天然植物の有効成分であって、リンゴまたは梨のような果物内でも発見される。また、抗炎症、抗がん、抗アレルギー、抗憂鬱、そして抗菌、抗真菌などの薬理的な効果を有しており、特に皮膚の生理活性と関連して抗炎症及び刺激緩和などの効果を有している。また、抗老化機能としてコラーゲンの生成に重要なプロコラーゲンの合成を促進し、老化防止に重要なセラミド及びフィラグリーンの合成を促進し、生成されたコラーゲンなどの高分子タンパク質を破壊する酵素であるMMP−1の活性を阻害することで、コラーゲンの生成は促進し、コラーゲンの破壊は防ぐ二重老化防止システムを有することが特徴である。このように皮膚のシワ改善に優れた効果のあるオレアノール酸は、その間に多様な乳化化粧品剤形のシワ改善原料として使用されてきたが、水にほとんど溶けない難溶性であるだけでなく、化粧品に適用しても安定度及び力価不安定の問題によって、一定の含量以上含むのに限界があった。特に、このような難溶性の性質のため、化粧水のような可溶化剤形には、オレアノール酸をシワ改善原料として直接的に使用することは不可能な実情であった。 While research on raw materials having anti-aging effects on skin without inducing skin side effects, oleanolic acid is applied to skin cosmetic compositions to exhibit excellent anti-aging effects on skin. discovered. Oleanolic acid, a type of hydroxypentacyclic terpene, is an active ingredient in many natural plants such as Eriobotrya japonica (loquata), Perilla frutescens, Staphyleohalocarpa, and is also found in fruits such as apples or pears. In addition, it has pharmacological effects such as anti-inflammatory, anti-cancer, anti-allergy, anti-depressive, antibacterial and anti-fungal. Especially, it has anti-inflammatory and stimulating effects related to the physiological activity of the skin. Have. It is an enzyme that promotes the synthesis of procollagen, which is important for the production of collagen as an anti-aging function, promotes the synthesis of ceramide and filler green, which are important for the prevention of aging, and destroys macromolecular proteins such as collagen produced. It is characterized by having a double anti-aging system that inhibits the activity of MMP-1 to promote collagen production and prevent collagen destruction. In this way, oleanolic acid, which has an excellent effect on improving skin wrinkles, has been used as a wrinkle-improving raw material in various emulsified cosmetic dosage forms, but it is not only slightly soluble in water but also cosmetics. Even if it is applied to the above, there is a limit to including a certain content or more due to problems of stability and instability. In particular, due to such poorly soluble properties, it has been impossible to directly use oleanolic acid as a wrinkle-improving raw material in solubilizing agents such as skin lotions.
最近、皮膚の脂質類似組成のナノ技術を利用してオレアノール酸の成分を100〜150nm大きさのナノエマルジョンにカプセル化し、天然多糖類のイヌリンを用いた高分子乳化剤で2次カプセル化することにより、安定性を高めて化粧品の剤形に関係なく、オレアノール酸を使用できる状況が展開されたが、乳化製品においては、このようにカプセル化されたオレアノール酸を剤形内に投入するとき、製造工程によるカプセルの破壊を防ぐために、50℃以下の温度及び低いホモ混合速度下で投入しなければならないという煩わしさがあり、特に可溶化剤形では、安定度及び力価不安定性が依然として存在している実情である。また、単純にオレアノール酸を使用することよりも、さらに多くの費用がかかるだけでなく、オレアノール酸のカプセル化のためにオレアノール酸に加えて追加的な原料を使用することにより、製品の使用感に良くない影響を与えることができる。 Recently, by using nanotechnology of skin lipid-like composition, oleanolic acid components are encapsulated in nanoemulsions with a size of 100-150 nm, and then secondary encapsulated with a polymer emulsifier using natural polysaccharide inulin. The situation where oleanolic acid can be used regardless of the cosmetic dosage form has been developed to improve stability, but in emulsified products, when oleanolic acid thus encapsulated is put into the dosage form, In order to prevent capsule breakage due to the process, there is annoyance that it must be introduced at a temperature of 50 ° C. or lower and a low homomixing speed, and in particular, in the solubilizer form, stability and titer instability still exist. It is the actual situation. It is not only more expensive than simply using oleanolic acid, but also the product feel by using additional ingredients in addition to oleanolic acid for oleanolic acid encapsulation. Can have a negative effect.
また、全世界的に有機農認証化粧品の市場が大きくなっている時点において、オレアノール酸は、唯一に天然由来のシワ機能性成分として認められたが、前に言及した皮膚の脂質類似組成のナノ技術を利用してオレアノール酸をカプセル化した場合には、有機農認証化粧品に使用できない成分が多数含まれているので、有機農認証化粧品の原料として使用できなくなる。 In addition, at the time when the market for organic agricultural certified cosmetics has grown globally, oleanolic acid was only recognized as a naturally-occurring wrinkle functional ingredient. When oleanolic acid is encapsulated using technology, many ingredients that cannot be used in organic agricultural certified cosmetics are contained, and therefore cannot be used as raw materials for organic agricultural certified cosmetics.
本発明は、上記した従来技術の問題点を解決するために、シワ改善効果に優れたオレアノール酸を他の追加的な原料を使用してカプセル化することなく、単独でナノリポソームに安定するように捕集させて、可溶化剤形に使用した化粧料組成物を提供することを目的とする。 In order to solve the above-mentioned problems of the prior art, the present invention is to stabilize oleanolic acid excellent in wrinkle improvement effect into nanoliposomes alone without encapsulating using other additional raw materials. An object of the present invention is to provide a cosmetic composition which is collected in a solubilizer and used in the form of a solubilizer.
上記した目的を達成するために、本発明は、ナノリポソーム内に捕集したオレアノール酸を有効成分として含有する化粧料組成物であって、前記オレアノール酸を捕集したナノリポソームが、
1)プロピレングリコール、グリセリン及びこれらの混合物で構成された群から選択される1種以上のポリオール成分と、水素化レシチンであるリン脂質成分とを混合して溶解してから、それに炭酸ジカプリリルである油性成分とオレアノール酸とを添加し、均一に混合して混合物を得るステップと、
2)ステップ1)の混合物を冷却させ、エタノールを添加した後、均一に混合するステップと、
3)ステップ2)の混合液に界面活性剤と水を添加した後、これを均一に混合するステップと、を含む製造方法で得られたものであり、前記水素化レシチンの含量は、組成物の総重量に対して、0.05〜1.0重量%であることを特徴とする化粧料組成物を提供する。
In order to achieve the above object, the present invention is a cosmetic composition containing oleanolic acid collected in nanoliposomes as an active ingredient, wherein the nanoliposomes collected oleanolic acid are:
1) Propylene glycol, glycerin and dissolved by mixing with one or more of the polyol component is selected, and a phospholipid component is water hydride lecithin from a group consisting of a mixture thereof, it in dicaprylyl carbonate Adding an oil component and oleanolic acid and mixing uniformly to obtain a mixture ;
2 ) Allow the mixture of step 1 ) to cool, add ethanol, and then mix uniformly;
3) Step 2) mixture was added a surfactant and water in the step of mixing this uniform, which was obtained by a manufacturing method including the content of the hydrogenated lecithin, the composition The cosmetic composition is characterized by being 0.05 to 1.0% by weight based on the total weight of the above.
本発明の化粧料組成物は、皮膚のシワ改善に効果的なオレアノール酸をナノリポソーム内に捕集させて剤形内に安定化することにより、ナノリポソームによって経皮吸収の速度が増加され、コラーゲンの合成を促進することで優れたシワ改善効果を提供し、また、オレアノール酸を安定化させるための追加的な原料を投入せずに製品製造の単価を減らすことができる。また、爽やかで吸収後の水分感のある使用感を提供することができ、全世界的に増加している有機農のシワ機能性化粧品に対する消費者の需要を充足させることができる。 The cosmetic composition of the present invention, by collecting oleanolic acid effective in improving skin wrinkles in nanoliposomes and stabilizing them in the dosage form, the rate of percutaneous absorption by nanoliposomes is increased, Promoting the synthesis of collagen provides an excellent wrinkle-improving effect, and can reduce the unit cost of product production without introducing additional raw materials for stabilizing oleanolic acid. In addition, it is possible to provide a refreshing and moist feeling after absorption, thereby satisfying the consumer demand for organic agricultural wrinkle functional cosmetics that are increasing worldwide.
本発明は、有効成分としてオレアノール酸を含有する化粧料組成物を提供し、前記化粧料組成物は、可溶化の形態で剤形化することができる。前記オレアノール酸は、ナノリポソーム内に捕集されており、ナノリポソームによって安定化させることにより、可溶化の剤形内でオレアノール酸の安定性及び溶解度を高めることができ、経皮吸収率を高めることができる。 The present invention provides a cosmetic composition containing oleanolic acid as an active ingredient, and the cosmetic composition can be formulated into a solubilized form. The oleanolic acid is collected in the nanoliposomes, and stabilized by the nanoliposomes can increase the stability and solubility of the oleanolic acid within the solubilized dosage form, increasing the transdermal absorption rate. be able to.
本発明で使用されるオレアノール酸は、天然由来のシワ機能性成分として唯一に認められたものであって、本発明では、組成物の総重量に対して0.0001〜5.0重量%、好ましくは0.0005〜1.0重量%の量で含有する。0.0001重量%未満の濃度では、明確な効果を期待することができず、5.0重量%超過の濃度では、含有量増加による明確な効果の増加が現れないだけでなく、剤形安定度に良くない影響を及ぼすからである。 The oleanolic acid used in the present invention is uniquely recognized as a naturally occurring wrinkle functional ingredient, and in the present invention, 0.0001 to 5.0% by weight based on the total weight of the composition, Preferably it is contained in an amount of 0.0005 to 1.0% by weight. If the concentration is less than 0.0001% by weight, a clear effect cannot be expected. If the concentration exceeds 5.0% by weight, not only a clear increase in the effect due to an increase in the content does not appear, but also the dosage form is stable. This is because it has a bad effect every time.
本発明の可溶化化粧料組成物を製造する時に形成されるナノリポソームは、リポソームの形態を有するもので、平均粒子直径が10〜500nmのリポソームを意味し、本発明で形成されるナノリポソームの大きさは、好ましくは50〜300nmである。ナノリポソームの平均粒子直径が300nmを超過する場合には、本発明で達成しようとする技術的効果のうち皮膚浸透の改善及び剤形安定性の改善が非常に微弱なためである。 The nanoliposome formed when the solubilized cosmetic composition of the present invention is produced has the form of a liposome and means a liposome having an average particle diameter of 10 to 500 nm. The size is preferably 50 to 300 nm. This is because, when the average particle diameter of the nanoliposome exceeds 300 nm, among the technical effects to be achieved by the present invention, improvement of skin penetration and improvement of dosage form stability are very weak.
本発明でオレアノール酸の安定化のために形成されるナノリポソームは、ポリオール、油性成分、界面活性剤、リン脂質、及び水を含む混合物によって製造される。また、可溶化化粧料組成物に含まれているオレアノール酸を捕集しているナノリポソームは、高圧乳化や別途の製造工程なしで単純に可溶化化粧料組成物を製造する時、自然に形成されることを特徴とする。 The nanoliposomes formed for the stabilization of oleanolic acid in the present invention are produced by a mixture comprising a polyol, an oily component, a surfactant, a phospholipid, and water. In addition, nanoliposomes that collect oleanolic acid contained in solubilized cosmetic compositions are formed spontaneously when producing solubilized cosmetic compositions simply without high-pressure emulsification or a separate manufacturing process. It is characterized by being.
本発明のナノリポソームを含む可溶化化粧料組成物に用いられるポリオールは、特に制限されず、好ましくは、プロピレングリコール、ジプロピレングリコール、1,3−ブチレングリコール、グリセリン、メチルプロパンジオール、イソプロピレングリコール、ペンチレングリコール、エリトリトール、キシリトール、ソルビトール及びこれらの混合物で構成された群から選択される1種以上である。また、前記ポリオールは、ナノリポソームを含む可溶化化粧料組成物の総重量に対して5〜50重量%、好ましくは15〜30重量%の量で使用される。 The polyol used in the solubilized cosmetic composition containing the nanoliposome of the present invention is not particularly limited, and is preferably propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isopropylene glycol. And one or more selected from the group consisting of pentylene glycol, erythritol, xylitol, sorbitol and mixtures thereof. The polyol is used in an amount of 5 to 50% by weight, preferably 15 to 30% by weight, based on the total weight of the solubilized cosmetic composition containing nanoliposomes.
本発明のナノリポソームを含む可溶化化粧料組成物に用いられる油性成分は、当業界に公知された多様なオイルが利用されることができ、好ましくは、ヘキサデカン及びパラフィンオイルのようなハイドロカーボン系オイル、エステル系の合成オイル、ジメチコン及びシクロメチコン系のようなシリコーンオイル、ひまわり油、トウモロコシ油、大豆油、アボカド油、ごま油、及び漁油のような動植物性オイル、エトキシ化アルキルエーテル系オイル、プロポキシル化アルキルエーテル系オイル、フィトスフィンゴシン(phytosphingosine)、スフィンゴシン及びスフィンガニンのようなスフィンゴ脂質、セレブロシドコレステロール、シトステロール硫酸コレステリル、硫酸シトステロール、C10-40脂肪アルコール、並びにこれらの混合物である。その使用量は、ナノリポソームを含む可溶化化粧料組成物の総重量に対して0.01〜10.0重量%であり、好ましくは1.0〜5.0重量%である。 As the oil component used in the solubilized cosmetic composition containing the nanoliposome of the present invention, various oils known in the art can be used, and preferably a hydrocarbon system such as hexadecane and paraffin oil. Oils, synthetic oils based on esters, silicone oils such as dimethicone and cyclomethicone, animal and vegetable oils such as sunflower oil, corn oil, soybean oil, avocado oil, sesame oil, and fishing oils, ethoxylated alkyl ether oils, propoxylated alkyl ether-based oil, phytosphingosine (phytosphingosine), sphingolipids such as sphingosine and sphinganine, cerebroside, cholesterol, sitosterol cholesteryl sulfate, sitosterol sulfate, C 10-40 fatty alcohols, list Mixtures thereof. The usage-amount is 0.01 to 10.0 weight% with respect to the total weight of the solubilized cosmetic composition containing a nanoliposome, Preferably it is 1.0 to 5.0 weight%.
本発明のナノリポソームを含む可溶化化粧料組成物に用いられる界面活性剤は、当業界に公知されたいずれのものを使用してもよい。例えば、本発明で界面活性剤としては、アニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤、及び非イオン性界面活性剤を使用することができ、好ましくは、アニオン性界面活性剤及び非イオン性界面活性剤を使用することができる。アニオン性界面活性剤の具体的な例としては、アルキルアシルグルタミン酸塩、アルキルリン酸塩、アルキル乳酸、ジアルキルリン酸塩及びトリアルキルリン酸塩を含む。非イオン性界面活性剤の具体的な例は、ポリソルベート、アルコキシル化アルキルエーテル、アルコキシル化アルキルエステル、アルキルポリグリコシド、ポリグリセリルエステル、及び糖エステルを含む。前記界面活性剤の使用量は、ナノリポソームを含む可溶化化粧料組成物の総重量に対して0.001〜5.0重量%であり、好ましくは0.1〜1.0重量%である。 As the surfactant used in the solubilized cosmetic composition containing the nanoliposome of the present invention, any surfactant known in the art may be used. For example, as the surfactant in the present invention, an anionic surfactant, a cationic surfactant, an amphoteric surfactant, and a nonionic surfactant can be used, and preferably an anionic surfactant And nonionic surfactants can be used. Specific examples of the anionic surfactant include alkyl acyl glutamate, alkyl phosphate, alkyl lactic acid, dialkyl phosphate and trialkyl phosphate. Specific examples of nonionic surfactants include polysorbates, alkoxylated alkyl ethers, alkoxylated alkyl esters, alkyl polyglycosides, polyglyceryl esters, and sugar esters. The amount of the surfactant used is 0.001 to 5.0% by weight, preferably 0.1 to 1.0% by weight, based on the total weight of the solubilized cosmetic composition containing nanoliposomes. .
本発明で形成されるナノリポソームにおいてリン脂質は、両親媒性脂質が利用され、天然リン脂質(例えば、卵黄レシチンまたは大豆レシチン、スフィンゴミエリン)及び合成リン脂質(例えば、ジパルミトイルホスファチジルコリン又は水素化レシチン)を含み、好ましくはレシチンである。特に、大豆または卵黄で抽出した天然由来の不飽和レシチンまたは飽和レシチンが好ましい。通常的に天然由来のレシチンは、ホスファチジルコリンの量が23〜95%、そしてホスファチジルエタノールアミンの量が20%以下である。本発明のナノリポソームを含む可溶化化粧料組成物の製造において、リン脂質の使用量は、可溶化化粧料組成物の総重量に対して0.01〜5.0重量%であり、好ましくは0.5〜2.0重量%である。 In the nanoliposomes formed in the present invention, an amphipathic lipid is used as the phospholipid, and a natural phospholipid (eg, egg yolk lecithin or soybean lecithin, sphingomyelin) and a synthetic phospholipid (eg, dipalmitoyl phosphatidylcholine or hydrogenated lecithin) ), Preferably lecithin. In particular, naturally derived unsaturated lecithin or saturated lecithin extracted with soybean or egg yolk is preferable. Usually naturally derived lecithin has a phosphatidylcholine content of 23-95% and a phosphatidylethanolamine content of 20% or less. In the production of the solubilized cosmetic composition containing the nanoliposome of the present invention, the amount of phospholipid used is 0.01 to 5.0% by weight with respect to the total weight of the solubilized cosmetic composition, preferably 0.5 to 2.0% by weight.
本発明のナノリポソームを含む可溶化化粧料組成物で用いられる水は、一般的に脱イオン化された蒸留水であり、水の使用量は、可溶化化粧料組成物の総重量に対して25.0〜90.0重量%である。 The water used in the solubilized cosmetic composition containing the nanoliposome of the present invention is generally deionized distilled water, and the amount of water used is 25 with respect to the total weight of the solubilized cosmetic composition. 0.0 to 90.0% by weight.
本発明の可溶化化粧料組成物は、オレアノール酸を含有することにより、特に優れたシワ改善効果を提供する抗老化用の組成物として使用される。 The solubilized cosmetic composition of the present invention is used as an anti-aging composition that provides a particularly excellent wrinkle-improving effect by containing oleanolic acid.
また、本発明の組成物は、その剤形において特別な制限はないが、透明または懸濁液状の外観および使用上の長所を考慮すれば、柔軟化粧水、栄養化粧水、スプレー、ミストまたはゲル等の基礎化粧料;ヘアトニック、ヘアエッセンス又はヘアトリートメントなどの養毛剤のような毛髪用化粧料組成物;その他の医薬品及び医薬部外品などに幅広く適用することができ、人の皮膚に塗布された時にも副作用なしで安全で且つ効果が優れた皮膚のシワ改善剤として使用することができる。 In addition, the composition of the present invention is not particularly limited in its dosage form, but in view of a transparent or suspension-like appearance and advantages in use, soft lotion, nutritional lotion, spray, mist or gel Basic cosmetics such as; hair cosmetic compositions such as hair tonics, hair essences or hair treatments; other pharmaceuticals and quasi-drugs can be widely applied and applied to human skin It can be used as a skin wrinkle improving agent that is safe and effective without side effects.
本発明の組成物は、脂肪物質、有機溶媒、溶解剤、濃縮剤及びゲル化剤、軟化剤、抗酸化剤、懸濁化剤、安定化剤、発泡剤、芳香剤、界面活性剤、水、イオン型若しくは非イオン型乳化剤、充填剤、金属イオン封鎖剤及びキレート化剤、保存剤、ビタミン、遮断剤、湿潤化剤、必須オイル、染料、顔料、親水性若しくは親油性の活性剤、脂質小胞、又は化粧品に通常的に用いられる任意の他成分のような化粧品学若しくは皮膚科学分野で通常的に用いられる補助剤を含有することができる。これらの補助剤は、化粧品学または皮膚科学分野で一般的に使用される量で導入される。 The composition of the present invention comprises fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water , Ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipids Adjuvants commonly used in the cosmetics or dermatological fields such as vesicles or any other ingredient normally used in cosmetics can be included. These adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.
以下、実施例及び試験例を通じて本発明をさらに具体的に説明する。しかし、以下の実施例、実験例及び製造例は、本発明に対する理解を助けるために例示の目的のみで提供されるものに過ぎず、本発明の範疇及び範囲がこれに限定されないことを明らかにする。 Hereinafter, the present invention will be described more specifically through examples and test examples. However, the following examples, experimental examples, and preparation examples are provided for illustrative purposes only to assist in understanding the present invention, and it is clear that the scope and scope of the present invention is not limited thereto. To do.
[参考例1]ナノリポソームで安定化されたオレアノール酸の可溶化化粧水の製造
下記の表1に記載された組成によって実施例1〜3及び比較例1〜4のシワ改善用の可溶化化粧水を製造した(単位:重量%)。
実施例1〜3は、本発明に係るナノリポソームを形成するとともに、前記ナノリポソームが含まれる可溶化化粧水であり、比較例1〜2は、実施例1〜3とは異なる一般的な可溶化剤を使用したものであり、比較例3は、オレアノール酸をカプセル化されたオレアノール酸ナノベースの形態で含むものである。比較例4は、オレアノール酸をエタノールとプロピレングリコール4:1の比率の混合物に溶解させたものである。
[Reference Example 1] Preparation of oleanolic acid-stabilized skin lotion stabilized with nanoliposomes Solubilized makeup for improving wrinkles of Examples 1 to 3 and Comparative Examples 1 to 4 according to the composition described in Table 1 below Water was produced (unit: wt%).
Examples 1 to 3 are solubilized lotions that form the nanoliposomes according to the present invention and that contain the nanoliposomes. Comparative Examples 1 and 2 are generally acceptable different from Examples 1 to 3. A solubilizer is used, and Comparative Example 3 contains oleanolic acid in an encapsulated oleanolic acid nano-based form. In Comparative Example 4, oleanolic acid was dissolved in a mixture of ethanol and propylene glycol 4: 1.
製造方法は、次の通りである。
1)成分1〜3とポリオールの成分4〜5を一度に投入し、80℃で加温溶解した後、成分6〜9を投入して均一に混合した。
2)1)の混合物を65℃で冷却した後、エタノール(成分10)を投入して十分に混合した。
3)成分11〜14の水相成分をあらかじめ均一に混合した後、65℃で加熱した後、2)の混合物と均一に混合した。
4)前記3)を室温で冷却して保管した。
The manufacturing method is as follows.
1) Components 1 to 3 and polyol components 4 to 5 were added at a time, heated and dissolved at 80 ° C., and then components 6 to 9 were added and mixed uniformly.
2) After the mixture of 1) was cooled at 65 ° C., ethanol (component 10) was added and mixed well.
3) The water phase components of components 11 to 14 were uniformly mixed in advance, then heated at 65 ° C., and then uniformly mixed with the mixture of 2).
4) The above 3) was cooled and stored at room temperature.
一方、比較例3の場合には、前記ステップ3)の次に、カプセル化されたオレアノール酸ナノベース(成分15)を投入する。 On the other hand, in the case of Comparative Example 3, after step 3), encapsulated oleanolic acid nanobase (component 15) is charged.
[試験例1]組成物の安定度評価
前記経時変化によるシワ改善用の可溶化化粧料組成物の安定度を調べるために、実施例1〜3及び比較例1〜4で製造した可溶化化粧水を室温、45℃の恒温槽及び−10℃から45℃に12時間の間隔で循環する恒温槽でそれぞれ1ヶ月間保管した後、外観の変化を観察した。
[Test Example 1] Composition Stability Evaluation Solubilized makeup produced in Examples 1 to 3 and Comparative Examples 1 to 4 in order to examine the stability of the solubilized cosmetic composition for improving wrinkles due to changes over time. The water was stored for 1 month in a thermostat bath at room temperature, 45 ° C. and a thermostat bath circulated from −10 ° C. to 45 ° C. at intervals of 12 hours, and the change in appearance was observed.
前記表2における結果を見れば、オレアノール酸をナノリポソームに捕集した実施例1〜3は、他の一般的な可溶化剤を使用した比較例1〜2よりも長期的に安定することが分かる。また、実施例2と比較例1〜2とを比較してみれば、オレアノール酸をナノリポソームに捕集して安定化させた実施例2で使用した界面活性剤の量が、比較に1〜2で使用した界面活性剤の量よりも、遥かに少ないことが分かる。これにより、ナノリポソームを形成してオレアノール酸を捕集する場合、剤形内に使用しなければならない界面活性剤の量をかなり減らせることが分かり、多量の界面活性剤を使用する場合の皮膚刺激に対する危険も避けることができる。 If the result in the said Table 2 is seen, Examples 1-3 which collected oleanolic acid in the nano liposome may be stabilized in the long term rather than Comparative Examples 1-2 which used another general solubilizer. I understand. In addition, comparing Example 2 with Comparative Examples 1-2, the amount of surfactant used in Example 2 in which oleanolic acid was collected and stabilized in nanoliposomes was compared with 1- It can be seen that it is much less than the amount of surfactant used in 2. This indicates that when nanoliposomes are formed to collect oleanolic acid, the amount of surfactant that must be used in the dosage form can be significantly reduced, and the skin when using large amounts of surfactant. Risk of irritation can also be avoided.
[試験例2]ナノリポソームを形成してオレアノール酸を安定化させた組成物と、カプセル化されたオレアノール酸を使用した組成物との使用感比較
前記実施例2及び比較例3の使用感を評価するために、実施例2及び比較例3で製造されたシワ改善用の可溶化化粧料組成物に対して官能試験を実施した。25〜35歳の女性20名を対象にして、それぞれのシワ改善用の可溶化化粧料組成物を一般的な使用法によって手の甲皮膚に塗布した後、使用感に対する満足度を評価するようにした。官能評価は、べたつき感、吸収感、保湿感、栄養感の総4項目であり、各項目に対して非常に優秀(10点)、優秀(7.5点)、普通(5点)、悪い(2.5点)、及び非常に悪い(0点)の基準に基づいて行い、この値を平均して下の表3に示した。
[Test Example 2] Comparison of feeling of use between a composition in which nanoliposomes are formed to stabilize oleanolic acid and a composition using encapsulated oleanolic acid In order to evaluate, a sensory test was carried out on the solubilized cosmetic composition for improving wrinkles produced in Example 2 and Comparative Example 3. For 20 women aged 25 to 35 years old, each wrinkle-improving solubilized cosmetic composition was applied to the back of the hand by a general usage method, and the satisfaction with the feeling of use was evaluated. . The sensory evaluation is a total of four items: stickiness, absorption, moisturizing, and nutrition. Very good (10 points), excellent (7.5 points), normal (5 points), and bad for each item. Based on the criteria of (2.5 points) and very bad (0 points), this value was averaged and shown in Table 3 below.
ナノリポソームを剤形内に形成してオレアノール酸を安定化させた実施例2と、カプセル化されたオレアノール酸を使用した比較例3とを比較してみる場合、同じ量のオレアノール酸を使用してもカプセル化されたオレアノール酸を使用した比較例3は、カプセル化されたオレアノール酸ナノベースを製造するために安定化物質を実施例2よりも約2.4重量%以上さらに使用するので、使用感に良くない影響を及ぼすということが分かり、使用感を比較した場合には、表3のように剤形内にナノリポソームを形成してオレアノール酸を安定化させた剤形の使用感が遥かに良いことが分かる。 When comparing Example 2 where nanoliposomes were formed in a dosage form to stabilize oleanolic acid and Comparative Example 3 using encapsulated oleanolic acid, the same amount of oleanolic acid was used. However, Comparative Example 3 using encapsulated oleanolic acid uses about 2.4% or more more of the stabilizing material than Example 2 to produce encapsulated oleanolic acid nanobases. When it was found that it had an unfavorable effect on the feeling and the feeling of use was compared, the feeling of use of the dosage form in which nanoliposomes were formed in the dosage form to stabilize oleanolic acid as shown in Table 3 was far You can see that it is good.
[試験例3]コラーゲン生合成促進効果の測定
前記実施例2のコラーゲン生合成促進効果に対して、コラーゲン生合成を促進すると知られているトコフェロール及びEGCGと比較して測定した。まず、ヒト線維芽細胞(fibroblast)(PromoCell,Germany)を24孔(well)に1孔当たり105個ずつ種まき(seeding)をして90%程度育つまで培養した。これを24時間の間に無血清DMEM培地で培養した後、無血清培地に溶かした実施例2、トコフェロール及びEGCGをそれぞれ10-4モル濃度で処理し
、24時間の間にCO2培養器で培養した。これらの上層液を取ってプロコラーゲン型(I)エライザ(ELISA)キット(procollagen type(I))を利用してプロコラーゲン(procollagen)の増減の有無を観察した。その結果は、下記の表4に示した。ここで、合成能は、非処理群を100にして対比したものである。
[Test Example 3] Measurement of collagen biosynthesis promoting effect The collagen biosynthesis promoting effect of Example 2 was measured in comparison with tocopherol and EGCG which are known to promote collagen biosynthesis. First, human fibroblasts (PromoCell, Germany) were seeded in 24 wells at a rate of 10 5 per well and cultured until they grew to about 90%. This was cultured in serum-free DMEM medium for 24 hours, then treated with Example 4 tocopherol and EGCG dissolved in serum-free medium at 10 -4 molar concentrations, respectively, and in a CO 2 incubator for 24 hours. Cultured. These upper layer solutions were taken, and the presence or absence of increase or decrease of procollagen was observed using a procollagen type (I) ELISA (ELISA) kit (procollagen type (I)). The results are shown in Table 4 below. Here, the synthetic ability is compared with the untreated group as 100.
前記表4から分かるように、実施例2の組成物は、コラーゲン生合成を促進し、これは、コラーゲン生合成を促進すると知られているトコフェロール及びEGCGと比較しても、遥かに優れた効果を提供することが分かる。 As can be seen from Table 4 above, the composition of Example 2 promotes collagen biosynthesis, which is far superior to tocopherol and EGCG, which are known to promote collagen biosynthesis. You can see that
[試験例4]皮膚吸収量の測定
皮膚吸収は、モルモットの皮膚を対象にしてフランツ透過セルを利用して測定した。試験の直前、モルモットの腹部の部分の皮膚を採取して平方1cm2の面積で切断した後、これを透過鏡の直径が0.9cmの透過セルに設置してクランプで固定した。皮膚の一方の面〔ドナー(donor)容器〕は、オレアノール酸をエタノールとプロピレングリコール(4:1)に溶解させた比較例4のサンプルと、ナノリポソームで形成してオレアノール酸を安定化させた実施例2のサンプルとを、それぞれ0.2gずつ塗布し、他方の面〔受容(receptor)容器〕は、精製水とエタノールが4:1の重量比で混合された溶媒と接触するようにし、試験時の温度は、実際の皮膚温度である32℃を維持した。試験の開始後、一定の時間間隔で溶媒の一部を採取した後、HPLCを利用して皮膚に吸収されたオレアノール酸の量を測定し、経過時間による塗布濃度当たりの皮膚吸収量(μg/cm2/重量%)に示した。その結果を下記の表5に示した。
[Test Example 4] Measurement of skin absorption The skin absorption was measured using a Franz permeation cell for guinea pig skin. Immediately before the test, the skin of the abdomen of the guinea pig was collected and cut in an area of 1 cm 2 square, and then placed in a transmission cell having a transmission mirror diameter of 0.9 cm and fixed with a clamp. One side of the skin (donor container) was formed with nanoliposomes and samples of Comparative Example 4 in which oleanolic acid was dissolved in ethanol and propylene glycol (4: 1) to stabilize oleanolic acid. The sample of Example 2 was applied in an amount of 0.2 g each, and the other surface (receptor container) was brought into contact with a solvent in which purified water and ethanol were mixed at a weight ratio of 4: 1. The temperature during the test was maintained at 32 ° C., which is the actual skin temperature. After the start of the test, a part of the solvent was collected at regular time intervals, and then the amount of oleanolic acid absorbed into the skin was measured using HPLC, and the amount of skin absorbed per application concentration over time (μg / cm 2 / weight%). The results are shown in Table 5 below.
<HPLC分析条件>
−カラム:Waters Novapak C18(3.9mm×250mm、4um)
−溶媒流速:1ml/分
−検出UV:210nm
−サンプル測定濃度:10〜100ug/mL
−サンプル注入量:20uL
−溶離液:MeOH/0.1% H3PO4=82/18
<HPLC analysis conditions>
-Column: Waters Novapak C18 (3.9 mm x 250 mm, 4 um)
-Solvent flow rate: 1 ml / min -Detection UV: 210 nm
Sample measurement concentration: 10 to 100 ug / mL
-Sample injection volume: 20 uL
-Eluent: MeOH / 0.1% H 3 PO 4 = 82/18
前記表5の結果からナノリポソームの形成により、オレアノール酸を安定化させた実施例2の経皮吸収量が遥かに優秀であることが分かる。 From the results of Table 5, it can be seen that the transdermal absorption amount of Example 2 in which oleanolic acid is stabilized by the formation of nanoliposomes is far superior.
Claims (7)
1)プロピレングリコール、グリセリン及びこれらの混合物で構成された群から選択される1種以上のポリオール成分と、水素化レシチンであるリン脂質成分とを混合して溶解してから、それに炭酸ジカプリリルである油性成分とオレアノール酸とを添加し、均一に混合して混合物を得るステップと、
2)ステップ1)の混合物を冷却させ、エタノールを添加した後、均一に混合するステップと、
3)ステップ2)の混合液に界面活性剤と水を添加した後、これを均一に混合するステップと、を含む製造方法で得られたものであり、
前記水素化レシチンの含量は、組成物の総重量に対して、0.05〜1.0重量%であることを特徴とする化粧料組成物。 A cosmetic composition containing oleanolic acid collected in nanoliposomes as an active ingredient, wherein the nanoliposomes collected oleanolic acid,
1) Propylene glycol, glycerin and dissolved by mixing with one or more of the polyol component is selected, and a phospholipid component is water hydride lecithin from a group consisting of a mixture thereof, it in dicaprylyl carbonate Adding an oil component and oleanolic acid and mixing uniformly to obtain a mixture ;
2 ) Allow the mixture of step 1 ) to cool, add ethanol, and then mix uniformly;
3 ) A step of adding a surfactant and water to the mixed solution of step 2 ), and then uniformly mixing this , and a production method comprising:
The cosmetic composition according to claim 1, wherein a content of the hydrogenated lecithin is 0.05 to 1.0% by weight with respect to a total weight of the composition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0116288 | 2010-11-22 | ||
KR1020100116288A KR101821207B1 (en) | 2010-11-22 | 2010-11-22 | Solubilization cosmetic composition containing oleanolic acid |
PCT/KR2011/008785 WO2012070804A2 (en) | 2010-11-22 | 2011-11-17 | Cosmetic composition containing an oleanolic acid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016144525A Division JP6231624B2 (en) | 2010-11-22 | 2016-07-22 | Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013542984A JP2013542984A (en) | 2013-11-28 |
JP6321962B2 true JP6321962B2 (en) | 2018-05-09 |
Family
ID=46146254
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013539759A Active JP6321962B2 (en) | 2010-11-22 | 2011-11-17 | Cosmetic composition containing oleanolic acid |
JP2016144525A Active JP6231624B2 (en) | 2010-11-22 | 2016-07-22 | Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016144525A Active JP6231624B2 (en) | 2010-11-22 | 2016-07-22 | Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected |
Country Status (6)
Country | Link |
---|---|
JP (2) | JP6321962B2 (en) |
KR (1) | KR101821207B1 (en) |
CN (1) | CN103221028B (en) |
HK (1) | HK1186963A1 (en) |
SG (1) | SG190131A1 (en) |
WO (1) | WO2012070804A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103830118A (en) * | 2014-03-26 | 2014-06-04 | 清华大学 | Application and use method of salidroside in preparing skin-care product for preventing skin photoaging |
CN103830116B (en) * | 2014-03-26 | 2017-01-04 | 清华大学 | Ligustilide prevents purposes and the using method of skin photoage skin care item in preparation |
JP6605794B2 (en) * | 2014-09-22 | 2019-11-13 | 株式会社ファンケル | Arginase 1 production promoter |
SG11201707136PA (en) * | 2015-03-02 | 2017-10-30 | Amorepacific Corp | Multilamella nanoliposome which contains skin lipid components, and preparation method therefor |
CN106309313A (en) * | 2016-08-24 | 2017-01-11 | 彭友莲 | Whitening facial cleanser and preparing method thereof |
KR20190079276A (en) * | 2017-12-27 | 2019-07-05 | 정한수 | Anti-aging cosmetics with nanoparticles-ingredient that solubilized insoluble oligoanionic acid and manufacturing method for anti-aging cosmetics |
CN108403751B (en) * | 2018-05-23 | 2021-04-06 | 阜阳师范学院 | Application of triterpenoid saponin in trichosanthes peel |
CN113413325B (en) * | 2021-05-31 | 2022-04-05 | 宝萃生物科技有限公司 | Lip plumping composition and preparation method and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100489701B1 (en) * | 2002-10-09 | 2005-05-16 | 주식회사 태평양 | Submicron-liposome containing highly concentrated triterpenoid and method for preparing thereof |
KR100654846B1 (en) * | 2004-12-02 | 2006-12-06 | 한국콜마 주식회사 | Cosmetic composition comprising nano size liposome and oil in water type emulsion and manufacturing method thereof |
KR20060087817A (en) * | 2005-01-31 | 2006-08-03 | 주식회사 태평양 | Anti-aging cosmetic composition |
KR100654841B1 (en) * | 2005-06-27 | 2006-12-06 | 한국콜마 주식회사 | Lipid solution composition and method for preparing nano particle cosmetics having analogous structure and composition of human skin and promoting the transepidermal absorption of physiologically active substances using the same |
WO2007078060A1 (en) * | 2005-12-30 | 2007-07-12 | Amorepacific Corporation | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same |
JP2007224012A (en) * | 2006-01-30 | 2007-09-06 | Fujifilm Corp | Enzymatically crosslinked protein nanoparticle |
ES2286953B1 (en) * | 2006-05-18 | 2008-12-16 | Universidad De Granada | FORMULATION OF NATURAL TRITERPENES AND BIOPHENOLS OBTAINED FROM THE OLEA GENDER IN LIPOSOMAS. |
CN1923178A (en) * | 2006-08-22 | 2007-03-07 | 河南大学 | Oleanolic acid liposome preparation, freeze dried powder injecta thereof and its preparation |
KR20080038812A (en) * | 2006-10-31 | 2008-05-07 | (주)아모레퍼시픽 | A cosmetic of sheet-type containing unsoluble material stably in a low viscosity level state |
KR100792629B1 (en) * | 2006-11-20 | 2008-01-09 | (주)아모레퍼시픽 | Skin whitening cosmetic composition containing oldenlandia diffusa extract stabilized with nano-liposome |
JP2008297241A (en) * | 2007-05-31 | 2008-12-11 | Fujifilm Corp | Anti-acne skin agent for external use |
CN101843623B (en) * | 2010-04-09 | 2012-03-14 | 澳门理工学院 | External fat-increasing preparation and application thereof |
CN101923178B (en) | 2010-08-16 | 2012-05-23 | 中国海洋石油总公司 | Sub-pixel matching-based towline dynamic acquisition influence eliminating method |
-
2010
- 2010-11-22 KR KR1020100116288A patent/KR101821207B1/en active IP Right Grant
-
2011
- 2011-11-17 JP JP2013539759A patent/JP6321962B2/en active Active
- 2011-11-17 CN CN201180055817.3A patent/CN103221028B/en active Active
- 2011-11-17 WO PCT/KR2011/008785 patent/WO2012070804A2/en active Application Filing
- 2011-11-17 SG SG2013034087A patent/SG190131A1/en unknown
-
2013
- 2013-12-30 HK HK13114369.9A patent/HK1186963A1/en unknown
-
2016
- 2016-07-22 JP JP2016144525A patent/JP6231624B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2012070804A2 (en) | 2012-05-31 |
CN103221028B (en) | 2016-04-20 |
KR20120054906A (en) | 2012-05-31 |
JP2016222694A (en) | 2016-12-28 |
JP2013542984A (en) | 2013-11-28 |
SG190131A1 (en) | 2013-06-28 |
KR101821207B1 (en) | 2018-01-24 |
CN103221028A (en) | 2013-07-24 |
JP6231624B2 (en) | 2017-11-15 |
HK1186963A1 (en) | 2014-03-28 |
WO2012070804A3 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6231624B2 (en) | Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected | |
KR101934208B1 (en) | Compositions for Moisturizing Skin Containing Vegetable Vernix Ingredients | |
KR100921959B1 (en) | Multi-Emulsified Vesicles Comprising a Multi Lamellar Liposome and Phospholipid Monolayer Nanoliposomes | |
JP6377381B2 (en) | Liposome composition | |
KR20130023912A (en) | Peptides stabilized using liposome and cosmeceutical composition thereof | |
KR101577874B1 (en) | Liquid crystal cosmetic composition having similar skin lipid composition and containing glucosylceramide, and preparation method thereof | |
KR101595530B1 (en) | Liposome composition having excellent effect of skin wrinkle improvement and skin whitening for accelerating percutaneous absorption | |
KR101176523B1 (en) | A Cosmetic Composition having phase transformation | |
JP2005179313A (en) | Method for producing base agent for skin cosmetic, and skin cosmetic | |
KR101176530B1 (en) | Cosmetic Compositions for Sliming | |
KR101142010B1 (en) | Cosmetic composition Comprising Moisture Quality Component As Active Ingredient | |
KR101862039B1 (en) | A cosmetic composition containing spicule powder and natural complex extract stabilized in nanoliposome | |
KR101325553B1 (en) | Cosmetic Composition for Protecting Skin Comprising Aminolevulinic acid Contained in Liquid Crystal Base | |
KR100570093B1 (en) | Cosmetic Compostion for Alleviating Skin Irritation Comprising Mung Bean Extract Stabilized in Nanoliposome | |
KR20100043748A (en) | Elastic liposome and composition of skin external application containing the same | |
KR20060057664A (en) | Composition for protection of hair comprising ceramide stabilized in nanoliposome as active ingredient | |
KR100858628B1 (en) | Cosmetic Composition for alleviating Skin Irritation Comprising Rumex Crispus L. Extract Stabilized in Nanoliposome | |
KR101716426B1 (en) | Skin external composition for alleviating itch comprising vernixcaseosamimetic lipid complex and arctium lappa seed extracts | |
KR20070071500A (en) | Stabilized nanovesicle containing oleaginous components and transparent cosmetic composition comprising the same | |
KR20230021435A (en) | Oil-in-water cosmetic composition comprising nanovesicles in which poorly soluble ingredients are stabilized | |
JP4592347B2 (en) | External preparation composition | |
KR20150078137A (en) | Cosmetic composition for improving skin wrinkle | |
KR102551901B1 (en) | Cosmetic composition with improved stability and multifunctional effects by double encapsulation of quercetin, and tetrahydrocurcumin in nano liposome vesicles and liquid crystal droplets, and method for manufaturing the same | |
JP5329489B2 (en) | External preparation composition | |
KR20230101213A (en) | Composition With Improved Stability And Transdermal Delivery Rate Of Red Ginseng Oil And Preparing Method Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140905 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150813 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151006 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160722 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160906 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20161104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180406 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6321962 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |